Drug Trial Radar · NCT06400615
Study That Tests AD109 in Patients Taking GLP-1 Drugs
Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
May 20, 2024
Primary completion
Dec 26, 2024
Study completion Dec 26, 2024
Sponsor
- Lead sponsor
- ApnimedIndustry
- Sponsor type
- Industry
- First posted
- May 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide
Conditions
- OSA
Interventions
AD109Drug
Oral administration at bedtime
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Objective (Adverse Events)Time frame: 6 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Pinnacle Research Group, LLC
Anniston, Alabama
Clinical Neuroscience Solutions, Inc
Jacksonville, Florida
Monroe Biomedical Research
Monroe, North Carolina
Clinical Neuroscience Solutions, Inc
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.